Table III.
Association of rs4939827 with tumor molecular characteristicsa
| Controls | Cases | OR (95% CI) | Cases | OR (95% CI) | Case-only analysis | |
|---|---|---|---|---|---|---|
| RUNX3 promoter unmethylated | RUNX3 promoter methylated | Methylation versus unmethylation | ||||
| TT | 600 | 142 | 1 | 25 | 1 | 1 |
| TG | 1120 | 254 | 1.07 (0.82–1.40) | 63 | 1.40 (0.79–2.50) | 1.43 (0.74–2.78) |
| GG | 538 | 95 | 0.66 (0.47–0.94) | 35 | 1.65 (0.87–3.12) | 2.97 (1.39–6.35) |
| P trend | 0.04 | 0.12 | 0.0053b | |||
| G allelec | 0.84 (0.71–0.99) | 1.27 (0.94–1.74) | 1.74 (1.18–2.56) | |||
| WT BRAF | Mutant BRAF | Mutant versus WT BRAF | ||||
| TT | 600 | 162 | 1 | 19 | 1 | 1 |
| TG | 1120 | 286 | 1.05 (0.81–1.35) | 41 | 1.09 (0.53–2.24) | 1.86 (0.77–4.48) |
| GG | 538 | 126 | 0.80 (0.58–1.09) | 24 | 1.64 (0.75–3.58) | 3.17 (1.19–8.47) |
| P trend | 0.19 | 0.21 | 0.02 | |||
| G allele | 0.90 (0.78–1.05) | 1.29 (0.86–1.93) | 1.77 (1.09–2.88) | |||
| LINE-1 methylation-high | LINE-1 methylation-low | Methylation-high versus low | ||||
| TT | 600 | 108 | 1 | 67 | 1 | 1 |
| TG | 1120 | 210 | 1.23 (0.91–1.66) | 115 | 0.92 (0.63–1.33) | 0.80 (0.51–1.27) |
| GG | 538 | 101 | 1.13 (0.80–1.60) | 43 | 0.57 (0.35–0.93) | 0.55 (0.31–1.00) |
| P trend | 0.48 | 0.03 | 0.05 | |||
| G allele | 1.06 (0.90–1.26) | 0.78 (0.62–0.98) | 0.75 (0.56–1.00) | |||
| CIMP-low/negative | CIMP-high | CIMP-high versus low/negative | ||||
| TT | 600 | 146 | 1 | 21 | 1 | 1 |
| TG | 1120 | 267 | 1.07 (0.82–1.40) | 50 | 1.53 (0.78–3.00) | 1.65 (0.76–3.59) |
| GG | 538 | 108 | 0.76 (0.55–1.06) | 24 | 1.41 (0.65–3.05) | 2.27 (0.93–5.56) |
| P trend | 0.15 | 0.40 | 0.07 | |||
| G allele | 0.89 (0.76–1.04) | 1.17 (0.81–1.68) | 1.50 (0.97–2.34) | |||
| MSI-L/MSS | MSI-H | MSI-H versus MSI-L/MSS | ||||
| TT | 600 | 159 | 1 | 21 | 1 | 1 |
| TG | 1120 | 268 | 1.00 (0.77–1.29) | 54 | 1.63 (0.85–3.14) | 1.93 (0.95–3.90) |
| GG | 538 | 120 | 0.79 (0.58–1.08) | 26 | 1.47 (0.70–3.09) | 1.99 (0.87–4.55) |
| P trend | 0.16 | 0.33 | 0.10 | |||
| G allele | 0.90 (0.77–1.04) | 1.19 (0.84–1.68) | 1.40 (0.94–2.07) | |||
| WT KRAS | Mutant KRAS | Mutant versus WT KRAS | ||||
| TT | 600 | 113 | 1 | 69 | 1 | 1 |
| TG | 1120 | 215 | 1.24 (0.91–1.67) | 113 | 0.86 (0.60–1.22) | 0.69 (0.44–1.09) |
| GG | 538 | 93 | 0.94 (0.65–1.36) | 55 | 0.77 (0.51–1.18) | 0.87 (0.50–1.51) |
| P trend | 0.85 | 0.23 | 0.51 | |||
| G allele | 0.98 (0.82–1.17) | 0.88 (0.71–1.09) | 0.91 (0.69–1.20) | |||
| WT PIK3CA | Mutant PIK3CA | Mutant versus WT PIK3CA | ||||
| TT | 600 | 139 | 1 | 31 | 1 | 1 |
| TG | 1120 | 251 | 1.07 (0.81–1.40) | 57 | 0.94 (0.56–1.58) | 0.85 (0.48–1.52) |
| GG | 538 | 120 | 0.90 (0.65–1.25) | 18 | 0.62 (0.31–1.23) | 0.64 (0.30–1.37) |
| P trend | 0.58 | 0.19 | 0.26 | |||
| G allele | 0.96 (0.82–1.12) | 0.81 (0.58–1.11) | 0.81 (0.56–1.17) | |||
| TP53 negative | TP53 positive | TP53 positive versus negative | ||||
| TT | 600 | 76 | 1 | 67 | 1 | 1 |
| TG | 1120 | 151 | 1.14 (0.81–1.61) | 120 | 1.15 (0.78–1.69) | 0.83 (0.50–1.39) |
| GG | 538 | 66 | 0.86 (0.56–1.31) | 51 | 0.84 (0.52–1.36) | 0.81 (0.43–1.55) |
| P trend | 0.54 | 0.56 | 0.50 | |||
| G allele | 0.94 (0.77–1.15) | 0.93 (0.74–1.17) | 0.90 (0.65–1.24) | |||
aORs and P-values are adjusted for age at sample collection, race, gender, regular aspirin use, regular NSAIDs use, BMI, physical activity, history of CRC in a parent or sibling, smoking status, alcohol consumption, consumption of beef, pork or lamb as a main dish, energy-adjusted calcium and folate intake and type of sample (more details in the text).
bBH-adjusted P-value = 0.0371.
cLog-additive model, representing the OR for each additional G allele as compared with TT.